The effects of azacitidine on the response and prognosis of myelodysplastic syndrome and acute myeloid leukemia involving a bone marrow erythroblast frequency of >50%
HI could be achieved even if erythroblasts were dominant in BM. The overall survival was also not inferior in erythroblast-predominant group. Azacitidine could be an option irrespective of the numbers of erythroid cells in BM.